We Are Developing Life-Changing Therapies Through the Use of Our Proprietary Technologies.
Advancing cell-based CAR T therapeutics targeting significant unmet need in B-Cell Non-Hodgkin lymphoma
- Significantly differentiated, proprietary approach to personalized CAR T therapy targeting tumor specific antigens that are independent of CD19 or other antigens common to all B-Cells.
- Building on the proven success of CAR T therapy
- Following established roadmap for significant early-stage value creation
XCART is a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens, with a demonstrated proof of mechanism in B-cell Lymphomas. The XCART technology, developed by The Scripps Research Institute in collaboration with the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, is believed to have the potential to significantly enhance the safety and efficacy of cell therapy for B-cell Lymphomas by generating patient- and tumor-specific CAR T cells.
- Collaboration with Pharmsynthez and multiple academic institutions in Eastern Europe to optimize the overall XCART™ workflow, including clinical manufacturing processes, and ultimately to conduct a first in-human study in B-cell Non-Hodgkin lymphoma (NHL) patients.
- Research and development collaboration with Scripps Research covering design and implementation of the preclinical development program, as well as method development activities supporting process development for clinical manufacturing.
Next generation half-life extension platform for biologics
- Takeda: ongoing royalty stream through license agreement
- Pharmsynthez: filed registration dossier in Russia for Epolong product candidate
- Potential to partner with additional pharmaceutical companies
PolyXen is a patent-protected enabling platform technology designed for protein or peptide therapeutics. It uses the natural polymer polysialic acid (PSA) to prolong a drug's circulating half-life and potentially improve other pharmacological properties. PolyXen has been demonstrated in human clinical trials to confer extended half-life to biotherapeutics such as recombinant human erythropoietin (rhEPO) and recombinant Factor VIII (rFVIII).
Xenetic is leveraging PolyXen by partnering with biotechnology and pharmaceutical companies. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and receives royalty payments under this agreement. Additionally, Xenetic’s partner, PJSC Pharmsynthez ("Pharmsynthez"), is leveraging the Company’s PolyXen® technology to improve the pharmacological properties of its Epolong (erythropoietin and polysialic acid conjugate) product candidate pursuant to a royalty-bearing collaboration agreement between the Company's wholly owned subsidiary, Lipoxen Technologies Limited, and Pharmsynthez's wholly-owned subsidiary, SynBio LLC. Pharmsynthez has reported that it has started the registration phase of Epolong by filing a registration dossier to obtain approval of Epolong in Russia for the treatment of anemia in patients with chronic kidney disease. The registration dossier is based on previously reported data from Pharmsynthez's Phase 3 clinical trials of Epolong in Russia, which reportedly demonstrated the efficacy of Epolong and its potential to reduce side effects.